An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Lonafarnib (Primary) ; Pravastatin; Zoledronic acid
- Indications Progeria
- Focus Therapeutic Use
- 18 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 18 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 14 Apr 2017 Planned number of patients changed from 45 to 85.